相关实验视频

Updated: May 5, 2026

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

GALNT14 遗传变异携带不同的预后值,与肝细胞癌中的不同巨细胞类型联系在一起

Yu-De Chu¹, Pei-Huan Ho^1,2, Wei-Ting Chen^1,2

¹Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.

Journal of hepatocellular carcinoma

|August 11, 2025

概括

一个单核酸多态 (SNP) 的新面板改善了手术后肝细胞癌 (HCC) 预后预测. 这个与GALNT14表达相关的小组与瘤透的M2巨细胞也相关,这表明HCC的免疫调节.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫学免疫学免疫学

背景情况:

手术切除后肝细胞癌 (HCC) 复发需要可靠的预后生物标志物.
单核酸多态 (SNP) GALNT14-rs9679162显示出有希望的结果,但仅仅具有有限的预测能力.

研究的目的:

确定一个SNP小组,以改善手术后的HCC预后预测.
调查这个SNP小组在调节瘤透免疫细胞 (TIICs) 中的作用.

主要方法:

全基因组关联研究 (GWAS) 和345名HCC患者的基因型鉴定 (15项探索,330项验证).
分析SNP和rs9679162之间的链接不平衡 (LD).
预后评估的卡普兰-梅尔生存率和考克斯比例危险模型.
对GALNT14表达和TIICs之间的相关性分析.

主要成果:

GWAS确定了39个与HCC预后相关的SNP位点;8个强度LD的SNP与rs9679162是显著的预测因素.
组合的SNP小组,特别是2+3组,在单独的rs9679162上表现出优越的预测性能.
在TIIC中,GALNT14表达与M2-巨细胞丰度相关.

结论:

一个SNP面板,包括来自LD与rs9679162的2组和3组的特定SNP,作为HCC的强有力的预后标志物.
GALNT14表达与M2巨细胞有关,这表明在HCC预后中存在潜在的免疫调节机制.

关键词:

国家统一党小组成员.遗传生物标志物是一种遗传生物标志物.肝细胞癌是肝细胞癌.个性化医疗是个性化的医疗.透到瘤中的巨细胞.

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...